Open AccessRed cell distribution width, a predictive factor in immunocompromised patients with COVID-19: A comparison retrospective study between cancer and kidney transplant patients
Author(s) -
Minoosh Moghimi,
Manijeh Jozpanahi,
Kasra Khodadadi,
Seyede Pegah Saeed,
Seyede Vanoushe Azimi Pirsaraie,
Nooshin Jalili
Publication year - 2022
Publication title -
european journal of translational myology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.271
H-Index - 6
eISSN - 2037-7460
pISSN - 2037-7452
DOI - 10.4081/ejtm.2022.10582
Subject(s) - medicine , retrospective cohort study , cancer , red blood cell distribution width , disease , kidney transplantation , kidney cancer , cohort , lactate dehydrogenase , kidney disease , oncology , kidney , surgery , biology , biochemistry , enzyme
We aimed to review the records of cancer and kidney transplant patients of out of 1135 COVID-19 patients, who were referred to our hospital (Valiasr) in Zanjan, from March 16th, 2020, to June 11th, 2020. This was single-center, historical cohort study. Patients were divided into different subgroups and compared of disease outcomes. The only predictor of death was lactate dehydrogenase (LDH). The rate of red cell distribution width (RDW) in patients with active cancer was higher than kidney transplant patients and was statistically significant. There was no statistically significant difference in mortality between active and non-active cancer groups. Female sex and low SpO2 has increased the chances of ICU admission. Patients with active cancer generally have severe and more complicated disease and RDW can be a predictable option.